Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05468905

China Longitudinal Aging and Cognitive Impairment Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
4,000 (estimated)
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
Sex
All
Age
40 Years – 99 Years
Healthy volunteers
Accepted

Summary

This is a multi-center longitudinal study that consists of five cohorts: cognitive normal aging (CN), Subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and vascular cognitive impairment (VCI). The goals of this study are as follow: 1.To establish longitudinal cohort study database containing comprehensive epidemiological data, neuropsychological test data, laboratory parameters, image data and biological samples. 2. To determine the risk factors of AD and other dementias. 3. To explore the conversion rates from CN to SCI, MCI or AD and the risk factors as well as biomarkers for the progression from CN to SCI, MCI or AD. 4. To explore and validate blood, CSF, urine, imaging and other biomarkers for the early detection and progression of AD.

Detailed description

As the population ages in China, the number of patients with neurocognitive disorders such as Alzheimer's disease (AD) and vascular cognitive impairment (VCI) is steadily increasing. The burden of cognitive impairment in China has been an important public health problem. Cohort study on aging and cognitive impairment is urgent to better understand and address this issue. Early prevention, diagnosis and treatment are critical for reduction the burden of cognitive impairment. In this prospective study, subjects will be recruited into one of the five groups based on inclusion and exclusion criteria: 1) CN, 2) MCI 3) AD and 4) VCI. Each of the subjects will be followed up at designated time points up to 5 years. Epidemiological data, medical, imaging (MRI and PET scans), genetic information and various biological samples will be collected during the baseline and follow-up period.

Conditions

Interventions

TypeNameDescription
OTHERNone of interventionNone of intervention

Timeline

Start date
2021-01-10
Primary completion
2025-12-01
Completion
2026-12-01
First posted
2022-07-21
Last updated
2022-07-21

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05468905. Inclusion in this directory is not an endorsement.